Daratumumab in Combination With High‐Dose Cytarabine and Amsacrine as an Effective Salvage Therapy and Bridge to Allogeneic Hematopoietic Stem Cell Transplantation for Refractory T‐Cell Acute Lymphoblastic Leukemia: A Case Report
ABSTRACT Patients with refractory or relapsed T‐cell acute lymphoblastic leukemia (R/R T‐ALL) have dismal outcomes. While immunotherapies are growing opportunities for B‐cell ALL, targeted therapies for T‐ALL remain limited. The CD38 antigen, steadily expressed on T‐ALL blasts, represents a relevant therapeutic target. Daratumumab, an anti‐CD38 monoclonal antibody routinely used in other hematologic malignancies, could be a promising treatment option for T‐ALL. We report here the achievement of a third complete response with the combination of daratumumab, high‐dose cytarabine (18 g/m 2 ), and amsacrine in an 11‐year‐old patient with highly aggressive relapsed T‐ALL, enabling subsequent allogeneic hematopoietic stem cell transplantation.
Authors
- Audrey Grain (ORCID: https://orcid.org/0000-0003-1547-8229)
- Baptiste Le Calvez (ORCID: https://orcid.org/0000-0001-5148-3792)
- Caroline Mayeur‐Rousse (ORCID: https://orcid.org/0000-0003-4070-3694)
- Perrine Moyer
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Centre Hospitalier Universitaire de Nantes (FR)
- Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Laboratoire de Thermique et Energie de Nantes (FR)
- Hôpital Robert-Debré (FR)
- Centre d'Investigation Clinique de Nantes (FR)
- Nantes Université (FR)
Publication Details
- Journal
- Pediatric Blood & Cancer
- Published
- 2026-09-16
- DOI
- https://doi.org/10.1002/1545-5017.70705
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 0.00